CAR-T Therapy for High-Risk B-Cell ALL: Improving Remission Rates in Children & Young Adults #ALL

Dr. Shannon Maude from Children's Hospital Philadelphia presents results from a groundbreaking trial using CAR-T cell therapy in children and young adults with high-risk B-cell acute lymphoblastic leukemia (ALL).

WHAT IS CAR-T THERAPY?
A type of immunotherapy that takes a patient's own immune cells (T-cells), reprograms them to recognize and attack leukemia cells, then returns them to the body.

THE CHALLENGE:
Some newly diagnosed ALL patients have minimal residual disease (MRD) after chemotherapy—meaning small amounts of cancer remain. These patients have a high risk of relapse with standard treatment alone.

THE TRIAL:
- Patients with persistent MRD are enrolled
- T-cells are collected and reprogrammed
- Patients continue chemotherapy while cells are being modified
- Modified cells are infused back
- No additional chemotherapy after CAR-T

KEY RESULTS:
- Historically: 39% of high-risk patients stay in remission at 5 years
- After CAR-T: 71% remission at 3 years, 64% at 5 years
- Significant improvement for children and young adults with high-risk disease

SIDE EFFECTS:
Most common: cytokine release syndrome (immune system activating like fighting an infection). Ranges from mild flu-like symptoms to severe. Most patients in this trial had mild effects because they started with low disease levels.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction
0:12 CAR-T Cell Therapy Trial Overview
0:26 How CAR-T Therapy Works
0:49 Why This Study is Different
0:56 MRD: The High-Risk Problem
1:09 How the Trial Works
1:42 Long-Term Outcomes: Before vs After
2:23 Side Effects & Cytokine Release Syndrome
2:49 Patient Experience in This Trial

#ALL #CAR-T #Leukemia #ClinicalTrial #Pediatric